- 129. (new) The antibody as in any one of claims 59-64, 76, 86-91, 103, 113-116, 121 or 122, wherein the antibody is conjugated to a detectable substance.
- 130. (new) A pharmaceutical composition comprising an antibody as in any one of claims 59-64, 76, 86-91, 103, 113-116, 121 or 122, and a pharmaceutically acceptable carrier.
- 131. (new) A kit comprising an antibody as in any one of claims 59-64, 76, 86-91, 103, 113-116, 121 or 122 and instructions for use, in one or more containers.--

REMARKS

Claims 1-58 were pending in this application. The Examiner has required restriction of the claims to one of six inventions. In response, Applicants hereby elect, with traverse, to prosecute the claims of Group III (Claims 11-16, 20, and 26-58), drawn to an antibody to a polypeptide.

Claims 1-58 have been canceled without prejudice to Applicants' right to pursue the subject matter of the canceled claims in subsequent applications. New Claims 59-131, directed to the elected subject matter, have been added. A copy of the pending claims is attached hereto as Exhibit A. Support in the specification for new Claims 59-131 can be found throughout, see, *e.g.*, page 86, line 35 to page 106, line 23. Applicants assert that no new subject matter, as defined in 35 U.S.C. § 132, has been added with the addition of new Claims 59-131.

Applicants have amended the specification to provide the patent deposit number assigned to the scFv clones deposited with the American Type Culture Collection (ATCC®). Applicants assert that the amendments do not add new subject to the specification. A copy of the replacement paragraphs of the portions of the specification which have been amended is attached hereto as Exhibit B.

Entry of the amendments and remarks made herein is respectfully requested.

Respectfully submitted,

Date January 25, 2001

Laura A. Coruzzi

Millan, C. Ly No.

50MONDS LLP 39, 201

1155 Avenue of the Americas

New York, New York 10036-2711

(212) 790-9090

Enclosure